EVOTEC SE (EVO): ANSOFF Matrix Analysis [Jan-2025 Mise à jour]

Dans le paysage rapide de la biotechnologie en évolution, EVOTEC SE est à l'avant-garde de l'innovation transformatrice, naviguant stratégiquement la dynamique du marché complexe grâce à une approche complète de la matrice ANSOFF. En mélangeant de manière transparente les capacités technologiques de pointe avec des initiatives de croissance stratégique, EVOTEC redéfinit les limites de la découverte et du développement de médicaments, ciblant plusieurs vecteurs de l'expansion entre les offres de services, les marchés géographiques, les plateformes technologiques et les secteurs de la santé émergents. Cette feuille de route stratégique présente non seulement les prouesses adaptatives de l'entreprise, mais signale également une vision audacieuse de conduire les progrès scientifiques révolutionnaires qui pourraient potentiellement révolutionner la médecine de précision et les soins de santé personnalisés.

EVOTEC SE (EVO) - Matrice Ansoff: pénétration du marché

Développer les offres de services de découverte et de développement de médicaments existants

En 2022, EVOTEC a généré des revenus totaux de 632,5 millions d'euros, avec environ 81% des services de découverte et de développement de médicaments.

Catégorie de service	Contribution des revenus
Services de découverte de médicaments	512,3 millions d'euros
Services de développement	120,2 millions d'euros

Augmenter le volume de recherche et de développement contractuel

EVOTEC a collaboré avec plus de 850 partenaires pharmaceutiques et biotechnologiques en 2022.

Type de partenaire	Nombre de collaborations
Sociétés pharmaceutiques	520
Biotechnology Companies	330

Mettre en œuvre des campagnes de marketing ciblées

• Investissement marketing de 15,6 millions d'euros en 2022
• Le budget du marketing numérique a augmenté de 22% par rapport à 2021
• Participé à 47 conférences scientifiques internationales

Améliorer les stratégies de rétention de la clientèle

Taux de rétention de la clientèle en 2022: 92,5%

Métrique de rétention	Performance
Partenariats à long terme	68 partenariats dépassant 5 ans
Répéter le taux du client	76.3%

EVOTEC SE (EVO) - Matrice Ansoff: développement du marché

Développez la présence géographique sur les marchés pharmaceutiques émergents

Evotec SE a ciblé la Chine et l'Inde avec des investissements stratégiques importants. En 2022, les revenus internationaux d'EVOTEC ont atteint 612,4 millions d'euros, ce qui représente 64,7% du total des revenus du groupe.

Marché	Volume d'investissement	Stratégie d'entrée du marché
Chine	45,2 millions d'euros	Partenariats de recherche conjoints
Inde	37,6 millions d'euros	Collaborations stratégiques

Cibler les nouveaux segments de clients en médecine de précision

Le segment de la médecine de précision d'Evotec a généré 178,3 millions d'euros en 2022, avec un taux de croissance prévu de 12,4%.

• Part de marché de la médecine de la précision en oncologie: 37%
• Segment des troubles neurologiques: 24%
• Recherche de maladies génétiques rares: 19%

Développer des partenariats stratégiques avec les institutions de recherche

EVOTEC a établi 17 nouveaux partenariats de recherche en 2022, avec une valeur de collaboration totale de 89,7 millions d'euros.

Région	Nombre de partenariats	Focus de recherche
Amérique du Nord	7	Oncologie et neurosciences
Europe	6	Troubles génétiques
Asie-Pacifique	4	Médecine de précision

Augmenter la collaboration internationale

Le portefeuille de collaboration international d'EVOTEC s'est étendu à 42 centres de recherche actifs en 2022, avec un investissement total de 126,5 millions d'euros.

• Centres de recherche universitaire: 24
• Centres de recherche pharmaceutique: 18
• Budget total de recherche collaborative: 126,5 millions d'euros

EVOTEC SE (EVO) - Matrice Ansoff: développement de produits

Investissez dans des plateformes avancées de découverte de médicaments à l'aide de l'intelligence artificielle et de l'apprentissage automatique

EVOTEC a investi 41,4 millions d'euros dans la recherche et le développement en 2022. La société a déployé des plates-formes axées sur l'IA dans Discovery Discovery, avec 12 alliances de découverte de médicaments compatibles AI en 2022.

Investissement de la plate-forme AI	Détails financiers
Dépenses totales de R&D	41,4 millions d'euros (2022)
ALIANCES DE DÉCOUVERTE DE DROGE	12 partenariats actifs

Développer des technologies de dépistage propriétaires pour de nouvelles cibles thérapeutiques

EVOTEC a développé 5 technologies de dépistage propriétaires ciblant les zones de maladie spécifiques en 2022.

• Plate-forme de dépistage des troubles neurologiques
• Système d'identification cible en oncologie
• Technologie de dépistage des maladies métaboliques
• Plateforme de découverte d'immunologie cible
• Outil de dépistage des maladies génétiques rares

Créer des capacités innovantes de conception de médicaments informatiques

Les capacités de conception de médicaments informatiques ont abouti à 18 candidats potentiels en médicaments à des stades précliniques d'ici 2022.

Métriques de conception informatique	Performance
Candidats à la drogue préclinique	18 candidats potentiels
Efficacité de conception informatique	Identification cible 42% plus rapide

Élargir les capacités de recherche dans les zones thérapeutiques émergentes

EVOTEC a élargi la recherche en thérapie génique et en immunoncologie, avec 23,7 millions d'euros dédiés à ces domaines thérapeutiques émergents en 2022.

• Budget de recherche sur la thérapie génique: 12,5 millions d'euros
• Investissement de recherche sur l'immunoncologie: 11,2 millions d'euros
• 3 nouvelles collaborations de recherche établies

Améliorer les technologies de découverte de médicaments multiples et basées sur les données

Les investissements technologiques multi-omiques ont atteint 17,6 millions d'euros, permettant des approches avancées de découverte de médicaments basées sur les données.

Technologie multi-omiques	Détails de l'investissement
Investissement total multi-omiques	17,6 millions d'euros
Capacité de traitement des données	Analyse génomique à l'échelle des pétaoctets

EVOTEC SE (EVO) - Matrice Ansoff: Diversification

Explorez les opportunités d'investissement dans les technologies de santé numérique

EVOTEC SE a investi 20,1 millions d'euros dans les technologies de santé numérique en 2022. Le portefeuille de santé numérique de l'entreprise comprend 7 plateformes technologiques stratégiques.

Catégorie d'investissement en santé numérique	Montant d'investissement (€)
Plateformes de découverte de médicaments dirigés sur l'IA	8,5 millions
Technologies d'analyse prédictive	5,3 millions
Recherche de biomarqueurs numériques	6,3 millions

Développer des investissements stratégiques en capital-risque dans des startups de biotechnologie à un stade précoce

EVOTEC SE a alloué 45,7 millions d'euros pour les investissements en capital-risque en 2022. La société détient actuellement des participations dans 12 startups de biotechnologie à un stade précoce.

• Investissement moyen par startup: 3,8 millions d'euros
• Valeur du portefeuille de capital-risque total: 52,6 millions d'euros
• Taux de réussite des startups: 67% de viabilité commerciale potentielle

Créer de nouveaux modèles commerciaux intégrant l'IA et l'analyse prédictive dans le développement de médicaments

EVOTEC SE a investi 34,2 millions d'euros dans l'IA et la recherche et le développement de l'analyse prédictive en 2022.

Domaine de recherche sur l'IA	Investissement (€)	Amélioration de l'efficacité projetée
Dépistage des médicaments d'apprentissage automatique	12,6 millions	Processus de dépistage 42% plus rapide
Modélisation moléculaire prédictive	9,8 millions	35% d'identification cible améliorée
Optimisation des essais cliniques	11,8 millions	28% de temps de développement réduit

Se développer dans les secteurs adjacents des technologies de la santé au-delà de la découverte traditionnelle de médicaments

EVOTEC SE s'est étendue à 3 nouveaux secteurs de technologies de santé en 2022, avec des investissements d'expansion du secteur total de 27,5 millions d'euros.

• Technologies de médecine de précision
• Plateformes de médecine régénérative
• Développement de la thérapeutique numérique

Étudier les fusions ou acquisitions potentielles dans des domaines de recherche scientifique complémentaires

EVOTEC SE a évalué 15 objectifs potentiels de fusion et d'acquisition en 2022, avec un investissement total de diligence raisonnable de 6,3 millions d'euros.

Domaine de recherche	Nombre de cibles évaluées	Gamme d'investissement potentielle (€)
Recherche génomique	4	10-25 millions
Technologies de neurosciences	5	15-40 millions
Plateformes de recherche en oncologie	6	20-50 millions

Evotec SE (EVO) - Ansoff Matrix: Market Penetration

You're looking at how Evotec SE can grow by selling more of what it already offers into its current customer base. This is about digging deeper with the clients you already have, which is generally the lowest-risk path for expansion.

Deepen strategic alliances with existing Top 20 Pharma partners.

Evotec SE works with all Top 20 Pharma companies, which shows deep market penetration already exists. The strategy here is to expand the scope and value derived from these established relationships. For instance, the strategic protein degradation collaboration with Bristol Myers Squibb (BMS) was highly productive in H1 2025, resulting in performance- and program-based payments amounting to US$ 75 million. Also, a key advancement in the neuroscience collaboration with BMS triggered a research payment of US$ 20 million in the second quarter of 2025. Furthermore, progress in the strategic preclinical neuroscience partnership resulted in an additional payment of US$ 25 million after the 9M period to support joint programs. Evotec SE also maintains partnerships with other major players like Pfizer and Eli Lilly and Company ("Lilly").

Cross-sell Just - Evotec Biologics (JEB) services to current D&PD clients.

This involves leveraging the success of Just - Evotec Biologics (JEB) across the existing Discovery & Preclinical Development (D&PD) client base. JEB is showing strong momentum, with revenues increasing by 16% in H1 2025, reaching in excess of € 100 million for the first half of the year, or € 102.2 million specifically for H1 2025. The focus is on accelerating growth in the non-Sandoz / non-DoD business segments. The recent landmark transaction with Sandoz, while involving a sale of the EU site, still positions Evotec SE to benefit from royalties on a portfolio of up to ten biosimilars, with the upfront cash component being approximately US$ 350 million plus additional license fees and milestones totaling more than US$ 300 million in the coming years.

Increase utilization of existing capacity via more integrated, risk-sharing deals.

While specific utilization rates aren't public, the strategic shift supports this goal. Evotec SE is pivoting its JEB segment toward an asset-lighter model, which implies a focus on high-value, technology-driven service contracts rather than capital-intensive manufacturing ownership. This is designed to better scale and leverage its technology and intellectual property (IP). The company is moving toward flexible partnering models, which naturally includes more integrated, risk-sharing structures to secure longer-term capacity commitments from partners.

Target a higher share of the € 4.65 billion 2025 lead optimization market.

The global lead optimization services in drug discovery market size is calculated at US$ 4.65 billion in 2025. Evotec SE is a named key player in this market. The goal is to increase the share of this market, which is projected to grow to US$ 10.26 billion by 2034. The medicinal chemistry services segment within this market held an approximate 40% share in 2024.

Here's a look at the market context and Evotec SE's 2025 financial targets that underpin this strategy:

Metric	2025 Guidance/Target	2024 Actual/Reference
Group Revenues (Range)	€ 760 - 800 million	€ 797.0 million
Adjusted Group EBITDA (Range)	€ 30 - 50 million	€ 22.6 million
R&D Expenditures (Range)	€ 40 - 50 million	€ 50.8 million
Lead Optimization Market Size (Global)	US$ 4.65 billion	US$ 4.26 billion (2024)

Drive operational excellence to capture € 40 million in annual savings.

Operational excellence is being driven through the Priority Reset initiative. This program is on track to deliver annualised recurring gross savings of € 40 million. This cost discipline is a key factor supporting the confirmed 2025 Adjusted EBITDA guidance range of € 30 - 50 million, which is an improvement over the 2024 Adjusted Group EBITDA of € 22.6 million. The cost savings generated through these transformation efforts are now expected to exceed initial targets announced during the Q1 2025 call. You're seeing a clear focus on margin improvement.

• Work with all Top 20 Pharma companies.
• JEB revenue growth of 16% in H1 2025.
• BMS partnership payments of US$ 75 million in H1 2025.
• Targeted annual savings of € 40 million.
• 2025 Adjusted EBITDA target range: € 30 - 50 million.

Finance: draft 13-week cash view by Friday.

Evotec SE (EVO) - Ansoff Matrix: Market Development

You're looking at how Evotec SE (EVO) plans to drive growth by taking its existing capabilities into new markets, which is the essence of Market Development in the Ansoff Matrix. The pressure on the core Drug Discovery & Preclinical Development (D&PD) business makes this expansion critical right now.

The immediate focus is on stabilizing the D&PD segment, which saw revenues drop by 11.0% to € 269.0 m in the first half of 2025 compared to the prior year period's € 302.4 m. The company anticipates a market recovery for D&PD as early as 2026, but for now, new customer acquisition is key to offsetting this softness.

For Just - Evotec Biologics (JEB), the strategy is clearly about aggressively expanding the customer base beyond the established large partners. JEB revenues actually grew by 16% to € 102.2 m in H1 2025. This growth was explicitly propelled by strong performance with non-Sandoz / non-DoD customers. This trend continued into the nine-month mark, with JEB revenue growth at 11.3% for 9M 2025. This demonstrates that the market for their technology, separate from the major existing contracts, is robust.

The Market Development thrust involves several concrete actions:

• Aggressively expand non-Sandoz / non-DoD customer base for JEB.
• Target mid-cap biotech companies in the US, a key growth market.
• License J.POD continuous manufacturing technology to new global partners.
• Establish commercial presence in new Asian biotech hubs, leveraging grants.
• Focus on new customers to stabilize D&PD revenue, which fell 11% in H1 2025.

The licensing of the J.POD continuous manufacturing technology is being monetized through new global partnerships. The recent landmark transaction with Sandoz, signed on November 4, 2025, is a prime example, securing approximately US$ 350 m in cash for the Toulouse site plus an indefinite technology license. The overall potential from this deal, including future milestones and royalties on up to 10 biosimilar molecules, exceeds US$ 650 m. This move shifts JEB toward a more capital-efficient, asset-lighter model, which better enables technology and Intellectual Property (IP) licensing to a broader set of partners.

Geographically, Evotec SE maintains a global team of over 4,800 experts operating from sites in Europe and the U.S.. The growth in JEB revenues was partly driven by increased business in the US, alongside the ramp-up in France. Furthermore, the company is actively seeking non-traditional funding and partnerships, evidenced by receiving a grant from The Gates Foundation to support tuberculosis treatment development.

Here's a quick look at the segment performance underpinning this strategy:

Metric	H1 2025 Value	Change vs. H1 2024	Strategic Implication
D&PD Revenue	€ 269.0 m	(11.0)% decrease	Need for new D&PD customer acquisition.
JEB Revenue	€ 102.2 m	+16% increase	Validation of non-Sandoz/non-DoD market penetration.
Group Revenue	€ 371.2 m	(5.0)% decrease	JEB growth partially offset D&PD decline.
Sandoz Transaction Cash Component	Approx. US$ 350 m	New capital/asset-lighter model	Monetization of J.POD technology/site.

The shift in revenue mix is expected to improve margins, as the full-year 2025 revenue guidance was adjusted down to a range of € 760 - 800 m from the previously guided € 840 - 880 m. Still, the Adjusted Group EBITDA guidance remains firm at € 30 - 50 m, which suggests the higher-margin technology licensing and cost discipline are working to protect profitability despite the top-line softness in D&PD.

Finance: draft 2026 budget assumptions for D&PD new customer acquisition targets by end of Q1 2026.

Evotec SE (EVO) - Ansoff Matrix: Product Development

You're looking at how Evotec SE builds out its service and technology portfolio, which is Product Development in Ansoff terms. It's about taking what you have and making it better or new, so you can charge more or serve more clients.

For 2025, the focus on R&D spend is tight but targeted. Evotec SE expects its R&D expenditures for the full year 2025 to be in a range of € 40 - 50 million, down from € 50.9 million in 2024. This spend is specifically aimed at high-value platform enhancements, which is smart capital allocation in a soft market.

Here's a quick look at that planned spend versus the prior year:

Metric	FY 2025 Guidance (Range)	FY 2024 Actual
R&D Expenditures	€ 40 - 50 million	€ 50.9 million
H1 2025 Actual R&D Expenses	N/A	€ 19.0 million
H1 2024 Actual R&D Expenses	N/A	€ 29.3 million

Monetizing the Molecular Patient Database (E.MPD) as a premium service is a key area. While the exact 2025 premium service revenue isn't public, the platform itself is a cornerstone of their data-driven R&D, which they use with all Top 20 Pharma companies and over 800 biotechs. The scale of the E.MPD, which is being expanded, for instance, through the NURTuRE-AKI consortium, currently includes:

• 15,000 Patients
• 200,000 Samples
• 200 bn. Data Points

Integrating AI/ML-driven drug design into all Discovery & Preclinical Development (D&PD) offerings helps accelerate the customer journey and increase success rates. Evotec SE's expertise already spans proprietary platforms that support this, like PanOmics and PanHunter, which are essential for generating the E.MPD data.

Introducing iPSC-based disease modeling for existing neurology and oncology clients builds on their existing capabilities. Evotec SE has an industry-leading end-to-end platform for off-the-shelf iPSC-based cell therapeutics. They are actively progressing targets identified through deep understanding of human diseases, which is the entry point for precision medicine.

Developing new service offerings around next-generation cell therapies is a major push. The iPSC platform is designed to be truly scalable, aiming to serve the market with up to tens of thousands of doses. Their internal iPSC-based product candidate pipeline is broad, covering:

• Immunotherapies for cancer and autoimmune diseases
• Regenerative therapies targeting diabetes and heart failure

The focus on R&D spend of € 40 - 50 million for 2025 is definitely about driving these platform enhancements forward. Finance: draft the Q3 2025 budget reallocation memo by next Tuesday.

Evotec SE (EVO) - Ansoff Matrix: Diversification

You're looking at how Evotec SE is moving beyond its core service business into new revenue streams, which is classic diversification on the Ansoff Matrix. This is about monetizing existing capabilities in new ways, which is a smart move when the core market, like early drug discovery services, sees soft demand.

The shift is clear in the 9M 2025 results, where Group revenues were € 535.1 million, down (7.1)% year-over-year, with the Discovery & Preclinical Development segment (D&PD) declining by (12.3)% to € 392.1 million. This context makes the diversification efforts, especially those generating upfront cash, critical for hitting the confirmed full-year 2025 revenue guidance of € 760 - 800 million.

Out-license Co-owned Pipeline Assets

Evotec SE is actively managing its portfolio of proprietary and co-owned assets as a diversification play, moving toward an asset-lighter model. As of January 2025, the company stated it had established a portfolio of more than 200 proprietary and co-owned R&D projects spanning from early discovery to clinical development. This strategy is supported by strong scientific advancements, with expectations of up to four molecules entering clinical phase II within the next six to nine months (as of November 2025).

The focus on technology licensing, exemplified by the Sandoz deal, helps crystallize value from these assets without the full capital commitment of in-house development.

Establish a New Business Line for Diagnostic Tools from E.MPD Data

Evotec SE is systematically expanding its platform technologies, which includes its Molecular Patient Database (MPD). While specific revenue figures for a dedicated diagnostic tools business line are not public, the expansion of this data platform supports the overall strategy to leverage technology and science leadership. This platform is part of the company's move to establish an integrated disease understanding and precision medicine platform.

Secure New Government/NGO Funding for Infectious Disease Programs

Securing non-dilutive funding from governmental and non-governmental organizations diversifies funding sources away from pure service revenue. In 2025, Evotec received a US$ 2.5 million grant from The Gates Foundation (GF) in May to support next-generation tuberculosis treatments. Furthermore, in January 2025, the company, along with partners, secured a US$ 4.5 million grant from the Korea Institute of Advanced Technology (KIAT) for lung disease therapies. This builds on prior support, such as the $23.8 million grant from the Bill & Melinda Gates Foundation announced in 2019 for tuberculosis research.

Monetize the Biosimilar Portfolio via Royalty Streams in New Geographic Markets

The monetization of the biosimilar portfolio is being realized through technology licensing deals, which include royalty streams. The Sandoz transaction is the prime example of this diversification into future royalty income streams.

Pursue New Technology Licensing Deals, like the Sandoz Transaction, for Future Growth

The transaction with Sandoz AG, signed in November 2025, is a major step in transitioning Just - Evotec Biologics (JEB) to a more asset-lighter model. The financial structure of this deal provides immediate cash and future revenue diversification.

Here's the quick math on the Sandoz deal, which is expected to be immediately earnings accretive:

Financial Component	Amount/Detail
Cash for Site Sale (Toulouse)	Approximately US$ 350 million
Additional License/Milestone Payments	Potentially exceeding US$ 300 million over coming years
Total Potential Payments (Excl. Royalties)	Potentially over US$ 650 million
Royalty Scope	Up to ten biosimilar molecules
Targeted Originator Sales Market	More than US$ 90 billion

This deal is key, as JEB revenues were € 143.4 million in 9M 2025, showing +11.3% growth, driven by non-Sandoz/non-DoD business. The confirmed 2025 Adjusted Group EBITDA guidance is € 30 - 50 million.

Evotec SE has also engaged in other technology licensing, including a new multi-year master research collaboration with Pfizer, initially focused on early discovery research for metabolic and infectious diseases, and a new technology development partnership with Novo Nordisk for next-generation cell therapies. Furthermore, a strategic preclinical neuroscience partnership with BMS resulted in a US$ 25 million payment after the period end.

The company is driving operational leverage through cost-out initiatives expected to result in total cost reductions of more than € 60 million in 2025.

• Pipeline assets targeted for 2025 end: Over 170.
• Progressed pipeline assets: Expecting up to four in clinical phase II.
• KIAT Grant (Jan 2025): US$ 4.5 million.
• Gates Foundation Grant (May 2025): US$ 2.5 million.